Endurant Capital Management LP Calliditas Therapeutics Ab Transaction History

Endurant Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$21.03 - $33.19 $3.04 Million - $4.79 Million	-144,393 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$26.02 - $31.17 $53,861 - $64,521	2,070 Added 1.45%	144,393 $4.25 Million
Q1 2021 May 17, 2021	BUY	$27.01 - $32.92 $3.84 Million - $4.69 Million	142,323 New	142,323 $3.92 Million
Q4 2020 Feb 16, 2021	SELL	$23.34 - $36.65 $2.6 Million - $4.09 Million	-111,467 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$21.61 - $25.69 $1.05 Million - $1.25 Million	-48,751 Reduced 30.43%	111,467 $2.68 Million
Q2 2020 Aug 14, 2020	BUY	$19.17 - $23.2 $3.07 Million - $3.72 Million	160,218 New	160,218 $3.72 Million

20.3K

Ticker CALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,624,800
Market Cap $1.06B
Description
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.